Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Mol Med Rep. 2017 Nov;16(5):6208-6213. doi: 10.3892/mmr.2017.7308. Epub 2017 Aug 22.
The aim of the present study was to investigate the effect and possible mechanism of pioglitazone (PIO) on the calcification of rat vascular smooth muscle cells (VSMCs) in vitro. β‑glycerophosphate (β‑GP; 10 mmol/l) was used to induce calcification of VSMCs treated with a range of concentrations (5, 10, 15 and 20 µmol/l) of PIO for 12 days. Calcium deposits were revealed by Alizarin red staining. Extracellular calcium content was detected using a calcium assay kit. Western blotting was used to measure the expression of α‑smooth muscle actin (α‑SMA), runt‑related transcription factor 2 (Runx2), bone morphogenetic protein‑2 (BMP2), β‑catenin, glycogen synthase kinase‑3β (GSK‑3β), phosphorylated (p)‑GSK‑3β and cyclin‑D1. A total of 10 mmol/l β‑GP, 20 µmol/l PIO and 20 µmol/l peroxisome proliferator‑activated receptor γ (PPAR γ) antagonist GW9662, was added to the cell culture media. The changes of the above indexes were observed. The calcium content in the calcification group, treated with high phosphorus, increased significantly compared with the controls (P<0.05) and all different concentrations of PIO reduced extracellular calcium content (P<0.05). Alizarin red staining was positive in calcified VSMCs and PIO (20 µmol/l) intervention group was almost negative. The expressions of Runx2, β‑catenin, p‑GSK‑3β, BMP2 and cyclin‑D1 increased significantly in the calcification group, and treatment with 20 µmol/l PIO downregulated the expression of all the above proteins, while upregulating the expression of α‑SMA. The PPAR γ antagonist GW9662 could partly inhibit the effect of PIO on calcified VSMCs. The results of the present study indicated that PIO can alleviate the calcification of rat aortic VSMCs induced by β‑GP via inhibiting the activity of the Wnt/β‑catenin signaling pathway.
本研究旨在探讨吡格列酮(PIO)对体外大鼠血管平滑肌细胞(VSMCs)钙化的作用及可能机制。采用β-甘油磷酸(β-GP;10mmol/L)诱导浓度为 5、10、15 和 20μmol/L 的 PIO 处理的 VSMCs 钙化 12 天。茜素红染色显示钙沉积。采用钙测定试剂盒检测细胞外钙含量。采用 Western blot 法检测α-平滑肌肌动蛋白(α-SMA)、 runt 相关转录因子 2(Runx2)、骨形态发生蛋白 2(BMP2)、β-连环蛋白(β-catenin)、糖原合成酶激酶 3β(GSK-3β)、磷酸化(p)-GSK-3β和细胞周期蛋白 D1 的表达。向细胞培养物中加入 10mmol/Lβ-GP、20μmol/LPIO 和过氧化物酶体增殖物激活受体γ(PPARγ)拮抗剂 GW9662。观察上述指标的变化。高磷处理的钙化组细胞内钙含量明显高于对照组(P<0.05),且所有不同浓度的 PIO 均降低细胞外钙含量(P<0.05)。茜素红染色阳性的钙化 VSMCs 中,20μmol/L PIO 干预组几乎为阴性。钙化组 Runx2、β-catenin、p-GSK-3β、BMP2 和 cyclin-D1 的表达明显增加,而 20μmol/L PIO 处理组则下调上述所有蛋白的表达,同时上调α-SMA 的表达。PPARγ拮抗剂 GW9662 可部分抑制 PIO 对钙化 VSMCs 的作用。本研究结果表明,PIO 通过抑制 Wnt/β-catenin 信号通路的活性,可减轻β-GP 诱导的大鼠主动脉 VSMCs 钙化。